Novo Nordisk’s experimental obesity drug, CagriSema, failed to outperform Eli Lilly’s Zepbound in a head-to-head, phase 3 trial

[cygnus]

Novo Nordisk’s experimental obesity drug, CagriSema, failed to outperform Eli Lilly’s Zepbound in a head-to-head, phase 3 trial, causing a sharp fall in Novo Nordisk shares. CagriSema achieved 23% weight loss at 84 weeks, while Zepbound (tirzepatide) delivered 25.5%. This setback reinforces Zepbound's position as a market leader in weight loss.

Novo Nordisk sinks 16% after weight loss drug fails to match Eli Lilly's in trial

Novo Nordisk stock fell over 16% Monday after it said its next-generation weight loss drug didn't meet its primary target.

www.cnbc.com

 

[HereKittyKitty]

23.3% is still meaningful. I realize it's not for the BP Wars but for patients, it is.

 

[Ragnar]

The changes in body weight between the groups are essentially the same. I really wish that these studies would incorporate Dexa Scans and tell us how much of the weight loss is fat vs muscle. This Is much more clinically relevant than total body weight loss considering that about 25% of body weight lost is muscle.

 

[cygnus]

Now CagriReta, that's where it's at!

Currently 4.25mg/week reta pinned Sunday, 750mcg/week cagri pinned Wednesday. That combo is working well for me.

 

[exploitedworkerbee]

I bet their result would be better if the cagrisema group didnt need a couple of hours napping every day.

 

[Dogmandu]

Not that different on paper, but side effect profiles are going be very different and favorable to Tirz.

Sema was the OG but is now obsolete. Cagri was novel but it's not a selective amylin agonist. We now know that selective amylin agonists (like Elora) have much more tolerable side effects. So CagriSema is a compromised franken-GLP.

As the OP said, stacking Reta with an Amylin agonist like Elora may be the comb to beat...if you want to get down to your birth weight.

 

[HereKittyKitty]

Sema is not obsolete. It has been improved upon but it is still effective. Ask anyone still using it or stacking with it. It's not the latest and greatest, no. People still use it; it is one tool of several.

 

[Jerrey]

Sema is not obsolete. It has been improved upon but it is still effective. Ask anyone still using it or stacking with it. It's not the latest and greatest, no. People still use it; it is one tool of several.

Additionally for some who as is the case with a friend of mine had allergic reactions to triz it is a effective option that is safe for them.

 

[Anami]

The changes in body weight between the groups are essentially the same. I really wish that these studies would incorporate Dexa Scans and tell us how much of the weight loss is fat vs muscle. This Is much more clinically relevant than total body weight loss considering that about 25% of body weight lost is muscle.

Im hearing more and more (docs and obesity experts) that the muscle loss is not only pure muscle but actually the fat in the muscle. It also turns out that people don't loose their strength which is a good indicator. This all needs more investigation and too early to conclude. I will not be surprised if true.

 

[SpiralJetty]

I don't understand why people don't stack a myostatin inhibitor with a glp-1 agonist to ensure they maintain or even increase their muscle mass while losing fat?

 

[Dogmandu]

I don't understand why people don't stack a myostatin inhibitor with a glp-1 agonist to ensure they maintain or even increase their muscle mass while losing fat?

We don't have safe/effective/approved myostatin inhibitors yet. Many of us are eagerly waiting. I can think of 3 in development, but they're monoclonal antibodies and will be $$ and not grey in the foreseeable future. There are a couple of peps that are marketed as such, but results and safety are questionable. In the meantime, enobosarm (Ostarine) has been tested with Sema and appears to help people hold onto muscle while shedding mostly fat. It was a small, 3 mg Phase 1 study, I believe. But Ostarine has liver and lipid side effects to watch out for.

 

[Sparky757]

My apologies to anyone with Novo Nordisk stock. I was in this study on the tirzepatide side, and I lost 30.1% of my bodyweight and also got completely yoked from lifting.

 

[Anami]

Well, not long after this:

https://www.fiercebiotech.com/biote...candidate-drives-20-weight-loss-phase-2-china

Interesting timing

 

[94brian49]

I still love Sema so much.

I am in the third week of Sema 3 mg + Reta 10 mg, it is chef kiss

TBH i feel that all GLP drugs are more or less the same in terms of appetite control. Maybe Tirz and Reta give you more advantage because they boost your energy expenditure, but tbh i feel it is not by much.

Just saying that if Reta didn't exist today, i would be more than happy to have only Sema.

Is Sema obsolete? No i don't think so, but it is more a loss of popularity imo, which is a good thing, so that i can enjoy Sema with cheaper price

 

[tubby]

My apologies to anyone with Novo Nordisk stock. I was in this study on the tirzepatide side, and I lost 30.1% of my bodyweight and also got completely yoked from lifting.

As a LLY shareholder, no hard feelings. Just upset that Nova's loss in stock price wasn't Lilly's immediate gain.

 

[DjJoshua]

My apologies to anyone with Novo Nordisk stock. I was in this study on the tirzepatide side, and I lost 30.1% of my bodyweight and also got completely yoked from lifting.

LOL I got a lot of LLY im good.

 

[HereKittyKitty]

I still love Sema so much.

Me too. I'm not ready to stack GLP/GIPs. Sema was good to me and then I maxed out. Wish I'd been aware of the higher dosing tests at the time. Now, I am stocked up on Tz for some time.

 

[CNCCurrency]

Is Sema obsolete? No i don't think so, but it is more a loss of popularity imo, which is a good thing, so that i can enjoy Sema with cheaper price

Most people always want the newest shiny thing